E Castro1, D Olmos, A Garcia, J J Cruz, R González-Sarmiento. 1. Department of Medical Oncology, Hospital Universitario de Salamanca, Paseo San Vicente, CP 37007, Salamanca, Spain, ecastromarcos@yahoo.es.
Abstract
INTRODUCTION: Anthracyclines have various mechanisms of action that in the end lead to DNA double-strand breaks. Single-nucleotide polymorphisms (SNPs) in DNA repair genes may alter the protein function, affecting DNA repair proficiency and, therefore, the efficiency of DNA damaging chemotherapy. We have analysed whether SNPs in DNA repair genes (XRCC1, XRCC3 and XPD) could be useful to predict the response to anthracyclines in patients with early-stage breast cancer (EBC). METHODS: Peripheral blood samples from 150 patients with EBC were used for genotyping XRCC3Thr241Met, XRCC1Arg399Gln and XPDLys751Gln. Genotypes were correlated with survival outcomes. RESULTS: Eighty-four patients received treatment with chemotherapy regimens containing anthracyclines. In this group, patients with XRCC1Arg399Arg had a significant improvement in 5-year Disease Free Survival (DFS) compared with those with the Arg/Gln and Gln/Gln variants (84 vs 46 %, p = 0.026). In the multivariate analysis, XRCC1Arg399Arg was reported as an independent prognostic factor for DFS (HR 0.4, CI-95 % 0.2-0.9, p = 0.035). Patients with the XRCC3 Met241Met genotype presented better 5-year OS than those carrying the Thr/Thr and Met/Thr variants (100 vs 70 %, p = 0.030). A multivariate analysis for OS confirmed the independent prognostic value of XRCC3 Met241Met (HR 0.15, CI-95 % 0.02-0.90, p = 0.048). These differences were not significant when patients receiving other chemotherapy treatments, different from anthracyclines, were also considered (n = 150). XPDLys751Lys was associated with older age at diagnosis than the Lys/Gln and Gln/Gln genotypes (65 vs 58 years, p < 0.0001). CONCLUSIONS: XRCC3Thr241Met and XRCC1Arg399Gln may be predictive of survival outcome in EBC patients treated with anthracycline-based chemotherapy regimens.
INTRODUCTION:Anthracyclines have various mechanisms of action that in the end lead to DNA double-strand breaks. Single-nucleotide polymorphisms (SNPs) in DNA repair genes may alter the protein function, affecting DNA repair proficiency and, therefore, the efficiency of DNA damaging chemotherapy. We have analysed whether SNPs in DNA repair genes (XRCC1, XRCC3 and XPD) could be useful to predict the response to anthracyclines in patients with early-stage breast cancer (EBC). METHODS: Peripheral blood samples from 150 patients with EBC were used for genotyping XRCC3Thr241Met, XRCC1Arg399Gln and XPDLys751Gln. Genotypes were correlated with survival outcomes. RESULTS: Eighty-four patients received treatment with chemotherapy regimens containing anthracyclines. In this group, patients with XRCC1Arg399Arg had a significant improvement in 5-year Disease Free Survival (DFS) compared with those with the Arg/Gln and Gln/Gln variants (84 vs 46 %, p = 0.026). In the multivariate analysis, XRCC1Arg399Arg was reported as an independent prognostic factor for DFS (HR 0.4, CI-95 % 0.2-0.9, p = 0.035). Patients with the XRCC3Met241Met genotype presented better 5-year OS than those carrying the Thr/Thr and Met/Thr variants (100 vs 70 %, p = 0.030). A multivariate analysis for OS confirmed the independent prognostic value of XRCC3Met241Met (HR 0.15, CI-95 % 0.02-0.90, p = 0.048). These differences were not significant when patients receiving other chemotherapy treatments, different from anthracyclines, were also considered (n = 150). XPDLys751Lys was associated with older age at diagnosis than the Lys/Gln and Gln/Gln genotypes (65 vs 58 years, p < 0.0001). CONCLUSIONS:XRCC3Thr241Met and XRCC1Arg399Gln may be predictive of survival outcome in EBCpatients treated with anthracycline-based chemotherapy regimens.
Authors: Ewelina Synowiec; Joanna Stefanska; Zbigniew Morawiec; Janusz Blasiak; Katarzyna Wozniak Journal: Mutat Res Date: 2008-10-10 Impact factor: 2.433
Authors: A A Rodriguez; A Makris; M F Wu; M Rimawi; A Froehlich; B Dave; S G Hilsenbeck; G C Chamness; M T Lewis; L E Dobrolecki; D Jain; S Sahoo; C K Osborne; J C Chang Journal: Breast Cancer Res Treat Date: 2010-06-26 Impact factor: 4.872
Authors: Maurizio Manuguerra; Federica Saletta; Margaret R Karagas; Marianne Berwick; Fabrizio Veglia; Paolo Vineis; Giuseppe Matullo Journal: Am J Epidemiol Date: 2006-05-17 Impact factor: 4.897
Authors: R de las Peñas; M Sanchez-Ronco; V Alberola; M Taron; C Camps; R Garcia-Carbonero; B Massuti; C Queralt; M Botia; R Garcia-Gomez; D Isla; M Cobo; M Santarpia; F Cecere; P Mendez; J J Sanchez; R Rosell Journal: Ann Oncol Date: 2006-01-11 Impact factor: 32.976
Authors: Ailith Pirie; Qi Guo; Peter Kraft; Sander Canisius; Diana M Eccles; Nazneen Rahman; Heli Nevanlinna; Constance Chen; Sofia Khan; Jonathan Tyrer; Manjeet K Bolla; Qin Wang; Joe Dennis; Kyriaki Michailidou; Michael Lush; Alison M Dunning; Mitul Shah; Kamila Czene; Hatef Darabi; Mikael Eriksson; Dieter Lambrechts; Caroline Weltens; Karin Leunen; Chantal van Ongeval; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Carl Blomqvist; Kristiina Aittomäki; Rainer Fagerholm; Taru A Muranen; Janet E Olsen; Emily Hallberg; Celine Vachon; Julia A Knight; Gord Glendon; Anna Marie Mulligan; Annegien Broeks; Sten Cornelissen; Christopher A Haiman; Brian E Henderson; Frederick Schumacher; Loic Le Marchand; John L Hopper; Helen Tsimiklis; Carmel Apicella; Melissa C Southey; Simon S Cross; Malcolm Wr Reed; Graham G Giles; Roger L Milne; Catriona McLean; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Maartje J Hooning; Antoinette Hollestelle; John Wm Martens; Ans Mw van den Ouweland; Federick Marme; Andreas Schneeweiss; Rongxi Yang; Barbara Burwinkel; Jonine Figueroa; Stephen J Chanock; Jolanta Lissowska; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Hermann Brenner; Katja Butterbach; Bernd Holleczek; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Jingmei Li; Judith S Brand; Keith Humphreys; Peter Devilee; Robert Aem Tollenaar; Caroline Seynaeve; Paolo Radice; Paolo Peterlongo; Siranoush Manoukian; Filomena Ficarazzi; Matthias W Beckmann; Alexander Hein; Arif B Ekici; Rosemary Balleine; Kelly-Anne Phillips; Javier Benitez; M Pilar Zamora; Jose Ignacio Arias Perez; Primitiva Menéndez; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Katarzyna Durda; Ute Hamann; Maria Kabisch; Hans Ulrich Ulmer; Thomas Rüdiger; Sara Margolin; Vessela Kristensen; Siljie Nord; D Gareth Evans; Jean Abraham; Helena Earl; Christopher J Poole; Louise Hiller; Janet A Dunn; Sarah Bowden; Rose Yang; Daniele Campa; W Ryan Diver; Susan M Gapstur; Mia M Gaudet; Susan Hankinson; Robert N Hoover; Anika Hüsing; Rudolf Kaaks; Mitchell J Machiela; Walter Willett; Myrto Barrdahl; Federico Canzian; Suet-Feung Chin; Carlos Caldas; David J Hunter; Sara Lindstrom; Montserrat Garcia-Closas; Fergus J Couch; Georgia Chenevix-Trench; Arto Mannermaa; Irene L Andrulis; Per Hall; Jenny Chang-Claude; Douglas F Easton; Stig E Bojesen; Angela Cox; Peter A Fasching; Paul Dp Pharoah; Marjanka K Schmidt Journal: Breast Cancer Res Date: 2015-04-22 Impact factor: 6.466
Authors: Manuel Luis Orta; Andreas Höglund; José Manuel Calderón-Montaño; Inmaculada Domínguez; Estefanía Burgos-Morón; Torkild Visnes; Nuria Pastor; Cecilia Ström; Miguel López-lázaro; Thomas Helleday Journal: Nucleic Acids Res Date: 2014-07-29 Impact factor: 16.971